Navigation Links
Clinical Data Reinforce Safety and Efficacy of Boston Scientific's Two Drug- Eluting Stent Platforms
Date:3/29/2009

NATICK, Mass. and ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed three-year results from the SPIRIT II Clinical Trial and a pooled meta-analysis of two-year data from the SPIRIT II and III Trials. SPIRIT II and SPIRIT III are prospective, randomized, non-inferiority trials with 300 and 1,002 patients respectively, designed to compare the safety and efficacy of the PROMUS(R) (XIENCE V(TM)) Everolimus-Eluting Coronary Stent to Boston Scientific's first-generation TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent. SPIRIT II three-year results were presented by Patrick W. Serruys, M.D., Ph.D, and the two-year meta-analysis was presented by Yoshinobu Onuma, M.D., at the 58th Annual Scientific Session of the American College of Cardiology.

The two-year pooled meta-analysis was intended to estimate the incidence of low frequency events or outcomes in key subgroups, and included 892 patients randomized to the PROMUS (XIENCE V) Stent and 410 patients treated with the TAXUS Stent. While overall pooled results and some subgroups at two years favored the PROMUS (XIENCE V) Stent for rates of Major Adverse Cardiac Events (MACE), the MACE results in patients with diabetes favored the TAXUS Stent.

"Clinical data presented at ACC continue to reinforce the value of Boston Scientific's two-drug portfolio," said Keith D. Dawkins, M.D., Associate Chief Medical Officer of Boston Scientific. "While the PROMUS (XIENCE V) Stent performed well against the TAXUS Stent in the meta-analysis, it is important to note that 96 percent of the control patients received the TAXUS Express Stent, making the comparison almost entirely based on our first-generation technology. Of particular interest is the subgroup data on diabetics given the recent discussion in scientific journal
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
3. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
4. RenalGuard(R) Pilot Safety Clinical Trial Data to be Presented at ACC 2009
5. Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing
6. Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients
7. Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
8. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
9. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
10. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
11. Another LNA-based RNA Inhibitor Enters Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... VILLAGE, Nev. , June 29, 2015  PDL ... it has entered into a credit agreement with CareView ... with up to $40 million of secured debt financing. ... industry focused on patient care monitoring. Under ... to $40 million of debt financing in two tranches ...
(Date:6/29/2015)... NESS ZIONA, Israel , ... Ltd. (Nasdaq: BVXV, TASE: BVXV) today announced positive preliminary ... M-001, BiondVax,s candidate for a universal influenza vaccine. In ... the ages of 50 to 65, followed by an ... 3 weeks later. M-001 was found to be safe ...
(Date:6/29/2015)... , June 29, 2015 DURECT ... James E. Brown , President and CEO, ... Conference on Wednesday, July 8 at 11:45 a.m. ... Le Parker Meridien Hotel in New York City.  ... may request a one-on-one meeting through the conference ...
Breaking Medicine Technology:PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 2PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 4BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3DURECT to Present at the Cantor Fitzgerald Healthcare Conference 2
... risk of,stroke by 34% in patient with atrial fibrillation or ... adequately treated by antithrombotic ... a,post-hoc analysis of the data from the ATHENA study were ... Society of Cardiology,congress 2008, in Munich, Germany. Previous results from ...
... in Subjects with ALS, RICHMOND, Calif., Sept. 3 ... that it has opened a Phase,2 clinical trial (SB-509-801) ... progressive, degenerative motor-neuron disease for which there,are limited treatment ... an injectable formulation of a plasmid,encoding a zinc finger ...
Cached Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5
(Date:6/30/2015)... Las Vegas, NV (PRWEB) , ... June 30, ... ... has recently returned to the U.S. after a 5-day tour in India. ... that are currently collaborating with Trivedi Master Wellness™ and Transformational Leader/Internationally ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... service and repair companies in San Diego. Bill Howe offers all employees ample ... through several organizations, but most notably through the local Plumbing-Heating-Cooling-Contractors of San Diego ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Some may ... – and the ongoing efforts of New York State Athletic Trainers’ Association (NYSATA) and ... NYSATA was recognized with two national awards, and a number of members also received ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... held October 28-31, 2015 at Disney’s Coronado Springs Resort in Lake Buena Vista, ... networking. Each year, this premiere event for psychiatric-mental health nursing draws more than ...
(Date:6/30/2015)... ... 2015 , ... Medflow, the leader in the ophthalmic EHR ... system from the company exclusively dedicated to helping eye care professionals for over ... solution combining modern cloud technology with Medflow’s proven expertise in the eye care ...
Breaking Medicine News(10 mins):Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 2Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 3Health News:Two Local San Diego Plumbers from Bill Howe Plumbing, Inc. Graduate from PHCC Academy 2Health News:Two Local San Diego Plumbers from Bill Howe Plumbing, Inc. Graduate from PHCC Academy 3Health News:NYSATA and Members Recognized with National Awards 2Health News:NYSATA and Members Recognized with National Awards 3Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 2Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 3Health News:Medflow Launches MEDFLOW 2.0 EHR – The Cloud-Based Ophthalmology EHR 2
... The North Desert Village landscaping experiment was conducted in ... of this experiment were that the graduate student families ... and fertile lawns and ornamental bushes spend time together ... in a nearby cluster of six homes on native ...
... New Orleans – The manner with which an individual ... rather than the chronological age, say leading researchers in ... is all about handling stress well and having a ... of studies on how stress hormones affect the brain, ...
... H.Influenza could be virtually abolished in Africa by routinely ... from the Oxford University have shown in their research ... H. influenza Type b (Hib) significantly reduced invasive Hib ... their findings in the Journal of the American Medical ...
... the UN Food and Agriculture Organisation (FAO) and the World ... an early warning system in order to spread awareness of ... animals to humans. ,Such a system has become imperative ... with alarming frequency. "The spread of avian flu reinforces the ...
... can also cause problems in men, according to a new ... at the Telethon Institute for Child Health Research // said ... in baby boys was now important. ,"The common ... affects girls, and that the genetic flaw would be so ...
... Institute in Sweden haves shown that the nerve cells of the ... ,The researchers explained that in a human body most of the ... example the cells of the liver take an approximate of two ... however found in their studies that the cells of the brain ...
Cached Medicine News:Health News:Environmental Surrounding Affects Human Behaviour 2Health News:Studying the psycho neurobiology of aging 2Health News:Studying the psycho neurobiology of aging 3Health News:Researchers claim That Regular Use Of Hib Vaccine In Africa Could Eliminate H. Influenza totally. 2Health News:Researchers claim That Regular Use Of Hib Vaccine In Africa Could Eliminate H. Influenza totally. 3Health News:Rett Syndrome In Men? 2Health News:Studies Show That Brain Cells Do Not Regenerate But Remain The Same Throughout 2
... acetabular cup system has been designed to ... tri-spiked and cluster hole configurations. The objective ... micromotion on three primary modes: Tilt, migration ... features result in initial and long-term fixation. ...
Optimal solution for normal acetabulum....
Optimal solution for normal acetabulum....
Biopro rimmed acetabular is manufactured from titanium and is porous coated on the outside of its shell. The rimmed acetabular accommodates a polyethylene inert....
Medicine Products: